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Abstract
Background: The spread of mammographic screening programs has allowed an increasing amount of early breast
cancer diagnosis. A modern approach to non-palpable breast lesions requires an accurate intraoperative localization, in
order to achieve a complete surgical resection. In addiction, the assessment of lymph node status is mandatory as it
represents a major prognostic factor in these patients. The aim of this study is to evaluate the reliability of a modified
technical approach using a single nanocolloidal radiotracer to localize both sentinel node and breast occult lesion.
Methods: Twenty-five patients with a single non-palpable breast lesions and clinically negative axilla were enrolled. In the
same day of surgery, patients underwent intratumoral and peritumoral administration of 99mTc-labeled nanocolloid tracer
under sonographic guidance. A lymphoscintigraphy was performed to localize the sentinel lymph node and its cutaneous
projection was marked on the skin in order to guide the surgeon to an optimal incision. During surgery an hand-held
gamma-detection probe was used to select the best surgical access route and to guide localization of both occult breast
lesion and sentinel lymph node. After specimen excision, the surgical field was checked with the gamma-probe to verify
the absence of residual sources of significant radioactivity, thereby ensuring a radical treatment in a single surgical session
and minimizing normal tissue excision.
Results: Both targeted breast lesion and sentinel lymph node were localized and removed at the first attempt in every
patients and histopathological diagnosis of malignancy was confirmed in 25/26 samples. Non-palpable lesions were
included within the surgical margins in all patients and in all samples surgical margins were free from neoplastic infiltration
thus avoiding any further reintervention. Only two patients showed metastatic involvement of sentinel lymph node.
Conclusions: The modified sentinel node and occult lesion localization (SNOLL) technique performed with a single
injection of nanocolloidal radiotracer has shown an excellent intraoperative identification rate of both non-palpable lesion
and sentinel lymph node. This procedure offers, as opposed to standard techniques, an accurate, simple and reliable
approach to the management of non-palpable breast cancer.
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Background
Over the last decades, the frequency of non-palpable
breast tumors has increased due to widespread of mam-
mographic screening programs and the development of
more accurate imaging technique [1–3]. As a result of
this trend, it has been reported a decrease in the mean
size of neoplastic lesions and a reduction in axillary
lymphatic involvement [4, 5]. The constant increase of
early, non-palpable breast cancer diagnosis requires a
comprehensive approach in order to achieve optimal
surgical treatment, as we already highlighted in breast
sarcomas [6, 7]. An ideal intraoperative localization pro-
cedure of non-palpable breast lesions should enable the
surgeon to accomplish a complete excision in a single
surgical session while avoiding excessive removal of nor-
mal tissue. Since its development, radioguided occult
lesion localization (ROLL) technique has been evaluated
as a more reliable procedure to guide the surgical resec-
tion of non-palpable breast lesions than hooked wire
technique [8–13]. In patients with early breast cancer
and non-palpable lesion the assessment of axillary lymph
node status is one of the major prognostic factor [14]. In
order to assess axillary lymph node status, sentinel
limph node (SLN) biopsy is now a widely accepted pro-
cedure for staging patients with early breast cancer, thus
avoiding them unnecessary complete axillary dissection
[15–19]. The possibility to perform ROLL and SLN
biopsy in the same surgical session, a procedure known
as sentinel node and occult lesion localization (SNOLL)
technique, has been evaluated in several studies by using
different tracers and sites of injection [20–24]. The aim
of this study is to evaluate the reliability of a modified
SNOLL approach characterized by a single injection of
unique nanocolloidal radiotracer for simultaneous occult
breast lesion and sentinel lymph node localization.
Materials and methods
Patients
Between November 2012 and October 2014, 25 female
patients with a single non-palpable breast lesion, were
enrolled for this study, based on preoperative cytologic
or histologic evidence. None of the patients had clinical
evidence of axillary disease, and all underwent radioguided
conservative surgery at the Departments of Radiological
Sciences and Surgical Sciences at “Sapienza” University of
Rome, Italy. The protocol was approved by the institu-
tional review committee, informed consent was obtained
from the patients and all procedures were in accord-
ance with the ethical standards of the responsible
institutional committee on human experimentation
and with the Helsinki Declaration of 1975, as revised
in 1983.
Instrumental diagnosis was based on X-ray mammog-
raphy (X-RM) and breast ultrasound (US); in selected
cases a breast magnetic resonance imaging (MRI) was
performed. Images were interpreted in accordance with
the breast imaging reporting and data system (BIRADS)
lexicon by radiologists experienced in breast imaging.
Patients with non-palpable breast lesion classified as
BIRADS 4, BIRADS 5, BIRADS 6 were included in the
study; preoperative diagnosis of malignancy or suspect
malignancy was obtained by Fine Needle Aspiration
Cytology (FNAC) or Core Biopsy. Patients with diffuse
microcalcifications, multifocal or multicentric lesions,
previous breast excisional biopsy or radiotherapy were
excluded.
Modified sentinel node and occult lesion localization
(SNOLL) technique
The modified SNOLL procedure was performed in a
one-day protocol with scheduled surgery. We used a
single nanocolloidal tracer (Nanocoll®, Gipharma srl,
Saluggia-VC-, Italy, average particle size <80 nm) labeled
with 99mTechnetium (99mTc); average radioactivity dose
was 35 MBq (range 20–70 MBq) in a volume of 0.4 ml.
On the same day of surgery, the nanocolloidal radio-
tracer was administered by the nuclear physician under
US guidance provided by a breast radiologist with
20 years of experience in the field of breast imaging
(10.5 MHz linear probe, Aplio XV, Toshiba); through a
22 G needle, half the dose of tracer was injected intratu-
morally (Fig. 1) in order to mark the clinically occult
breast lesion, while the other half was equally divided
between the opposite poles of the lesion (peritumoral
injection) to identify the lymphatic drainage pathway
towards SLN (Fig. 2). The entire procedure was carried
out without extracting the needle between the two
administrations. After radiotracer injection, all patients
were sent to the Nuclear Medicine Unit where lymphos-
cintigraphy was performed: images were acquired with
Fig. 1 US-guided intralesional injection of nanocolloidal radiotracer
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the patient positioned supine with the arm ipsilateral to the
lesion in maximum abduction, using a dual-head gamma
camera (Millenium MG, GE Medical Systems, Wisconsin,
USA) with low-energy, high-resolution parallel-hole
collimators. Early dynamic acquisitions were obtained
in oblique anterior (OA) projection for 20 minutes
(64×64 matrix, 1 image/minute), then static images
were performed in OA and lateral position with an ac-
quisition time of 300 seconds in a 128×128 matrix.
After the visualization of the lymphatic drainage path-
way and SLN, its cutaneous projection was identified
thanks to 57Co scintigraphic tracer and marked on the
skin with permanent ink to provide a guide for an opti-
mal surgical incision.
Surgery
Each patient underwent conservative surgery on the
same day of radiotracer injection. A hand-held gamma-
detection probe (GDP - Node Seeker™ 800, IntraMedical
Imaging, CA, USA) set to 99mTc photo-emittance peak
(140 keV ± 20 %) was used by the surgeon on intact skin
to select the best surgical access route, then the same
probe was introduced in the incision at different angles
to detect the area of maximal radioactivity in the surgi-
cal field and to define margins of resection (Fig. 3). After
radio-guided excision, breast tissue specimen was ori-
ented on three points and double-checked with GDP
once moved away from the surgical field, then γ-probe
was used to verify the absence of residual areas of
significant radioactivity in resection field; the surgeon
applied the same research technique to identify and
remove SLN (Fig. 4). If the breast lesion was in the
upper outer quadrant, the incision used to remove the
lesion was the same to access also the SLN, thus achiev-
ing a better cosmetic outcome; if the lesion was in
another quadrant, a separate axillary incision was per-
formed to remove SLN.
Pathological examination
Histological examination of the surgical specimen was
carried out by a pathologist specialized in breast dis-
eases. Breast tissue specimens were examined macro-
scopically to determine dimensions of the excised tissue,
presence and size of the lesion and microscopically to
assess the nature of the lesion, resection margins’ size
and their eventual neoplastic infiltration. SLN was ana-
lyzed in serial sections with haematoxylin-eosin staining
and immunohistochemistry with anti-cytokeratine anti-
bodies (clone MNF116) to assess the presence of macro-
metastases, micrometastases or isolated tumor cells.
Results
Initially, fourty patients with a clinically occult breast le-
sion detected by X-RM or US imaging and charachter-
ized by FNAC or Core Biopsy were consecutively
Fig. 2 US-guided perilesional injection of nanocolloidal radiotracer
Fig. 3 Intraoperative radio-guided excision of occult breast lesion
Fig. 4 Intraoperative radio-guided localization and excision of
sentinel node
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evaluated; all patients had no clinical evidence of axillary
disease. According to trial exclusion criteria, 6 patients
were excluded because of diffuse microcalcifications at
X-RM, 3 patients were excluded because multifocal or
multicentric lesions were detected during MRI evalu-
ation, 2 patients were excluded for previous excisional
biopsy on the same breast, 1 patient was excluded for
previous breast radiotherapic treatment and 3 patients
were excluded because non-malignant lesion was diag-
nosed by FNAC or Core Biopsy, for a total of 15 patients
excluded. The remaining 25 patients with imaging report
(X-RM, US and MRI) of single non-palpable breast le-
sion and clinically negative axilla were enrolled for the
study. One patient showed a clinically occult breast le-
sion in both breasts so that she underwent bilateral
SNOLL procedure. As a result, we targeted a total of 26
clinically occult breast lesions. Mean age of patients was
60 years (range 43–81 years); 5 patients (20 %) were in
menopause and 20 patients (80 %) were postmenopausal.
Preoperative lesion characteristics are shown in Table 1.
After intratumoral radiotracer injection, clinically occult
breast lesion was successfully identified by using the
γ-detection probe and removed at the first surgical
session in every patient. The evaluation of surgical
field by using γ-probe demonstrated the absence of re-
sidual areas of significant radioactivity in resection
field in all cases. Histological examination of the surgical
specimens confirmed malignancy in 25 patients (96 %); in
one patient there was evidence of non-malignant lesion
(this patient had a breast lesion classified as BIRADS 4 at
imaging and C3 at FNAC). Every breast lesion (mean size
8 mm, range 4–18 mm) was included within the surgical
margins, which were free from neoplastic infiltration, thus
avoiding any further re-intervention. The closest resection
margin was 1 mm in 3 patients. Complete results of the
final histological examination are shown in Table 2.
Lymphoscintigraphy showed axillary drainage pattern
in all patients; a single SLN was identified in 24 patients,
while in two patients were localized two SLN. Lymphos-
cintigraphic findings were always confirmed during sur-
gery by using γ-probe and SLN was found and removed
in every patient.
A total of 35 lymph nodes were isolated at final histo-
pathological examination (average excised lymph nodes
per patient 1,4); 32/35 lymph nodes were free from
metastatic involvement, two SLN showed macrometas-
tases (>2 mm) so patients were addressed to complete
axillary dissection, while in one patient SLN showed
Table 1 Preoperative lesion’s characteristics
No. of lesions %
Age
Mean 60
Range 43-81
Breast quadrant
Upper outer 17 65 %
Inferior inner 2 7 %
Upper inner 6 24 %
Inferior outer 1 4 %
Radiological diagnosis
BI-RADS 4 13 50 %
BI-RADS 5 11 42 %
BI-RADS 6 2 8 %
Cytological (C) or
histological (B) diagnosis
C3 4 15 %
C4 6 23 %
C5 8 31 %
B4 2 8 %
B5 6 23 %
Table 2 Final histopathological findings
No. of Patients %
Dimensions
Mean 8 mm
Range 4-18 mm
Histological diagnosis
Invasive ductal carcinoma (IDC) 6 23
IDC + ductal carcinoma (DC) in situ 11 42
DC in situ 4 15
Invasive lobular carcinoma (ILC) 2 7
Tubular Carcinoma 1 4
Tubular Carcinoma + 1 4
DC in situ
No evidence of malignancy 1 4
Grading
G1 9 36
G2 10 40
G3 6 24
Resection margins (mm)
1 3 12
2 5 20
3 0 0
4 3 12
5 6 24
6 2 8
7 1 4
8 1 4
9 0 0
>10 4 16
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isolated tumor cells (Table 3) whose malignant poten-
tial and prognostic significance are still under debate
[25–27]. Post-operative TNM classification is shown in
Table 4. The entire modified SNOLL procedure was
well tolerated by all patients and no complications were
observed.
Discussion
Clinical presentation of breast cancer is changing thanks
to mammographic screening programs and greater
awareness among women. The increasing frequency of
non-palpable breast lesions, characterized by low risk of
metastatic lymph nodes at diagnosis [28], requires an
approach aimed at both accurate intraoperative
localization of occult neoplastic lesions and reliable SLN
identification. As a matter of fact, several imaging
techniques are used to detect metastasis from different
types of cancers [29]. Gamma detection probe is more
frequently indicated for two surgical procedures: SLN
sampling (for breast cancer and melanomas) and
minimally-invasive radioguided surgery of parathyroid
adenomas [30, 31].
In this study, the modified SNOLL technique character-
ized by simultaneous intra- and peri-tumoral US-guided
injection of nanocolloidal tracer has shown an excellent
localization rate of both occult breast lesion and SLN.
The choice of a single-day protocol characterized by
radiotracer injection and lymphoscintigraphy performed
on the morning of surgery, when compared with ap-
proaches previously described such as the one proposed
by Feggi et al. [20], allowed to improve time manage-
ment and to reduce radioactive exposure to patients.
In addition, radiotracer administration under US guid-
ance was easy to perform and provided a real-time con-
trol of needle position, permitting an accurate injection
of the tracer. Nanocolloidal radiotracer injected intratu-
morally remains in the inoculation site for the necessary
time to enable the surgeon to select the optimal surgical
access route to the lesion and to perform an efficient
tumor localization and excision through the constant
orientation provided by γ-probe. Furthermore, after each
radio-guided excision the surgeon was able to perform a
check on the surgical field to confirm the absence of
neoplastic tissue residual immediately. This approach
allowed a limited breast conserving treatment and en-
sured disease-free resection margins in a single surgical
session. In our series, as demonstrated by histopatho-
logical analyses of the surgical specimens, the modified
SNOLL procedure permitted a complete excision of the
lesion at the first attempt in every patient, with no need
of re-intervention for involved resection margins. Lim-
ited breast tissue excision allowed a better cosmetic out-
come for patients improving patient compliance and
potentially reducing subsequent plastic surgery. SLN
identification obtained with bipolar perilesional tracer
injection, allowed an accurate study of lymphatic drain-
age pathway and a selective surgical removal of the SLN
identified with γ-probe, avoiding unnecessary complete
axillary dissection and its surgical complications, such as
chronic arm lymphedema and paraesthesias [32–35]. In
our series, 88.9 % of patients had no metastasis at the
frozen section histological examination of the SLN and
only in two patients complete axillary dissection was
required because of SLN macrometastasis detection.
Conclusions
In conclusion, this pilot study shows that, as opposed to
standard techniques (i.e., radioguided sentinel lymph
node biopsy performed on the day prior surgery and
radio-guided occult lesion localization performed on the
day of surgery), the modified SNOLL technique is an
accurate and easy-to-perform procedure. Indeed, it
allows, following intra- and peri-tumoral injection of a
single nanocolloidal radiotracer under US guidance, both
tumor excision and SLN removal in a single surgical
session reducing re-intervention rate and unnecessary
complete axillary dissection. It is worth to remember
that the procedure doesn’t require any particular radio-
protection measure due to the extremely low-dose ex-
position of the operating staff, as assessed by Cremonesi
[36]. This procedure improves resource and time man-
agement of early, non-palpable breast cancers increasing
comfort for patients.
Table 3 Status of removed lymph-nodes (LNs)
No. of LNs %
Free from metastatic involvement 32 91
Isolated Tumor Cells 1 3
Micrometastases 0 0
Macrometastases 2 6
Table 4 Postoperative pTNM classification
No. of patients %
pT
pTis 2 8.33
pT1a 3 12.5
pT1b 15 62.5
pT1c 3 12.5
pT2a 1 4.16
pN(sn)
pN0 21 87.5
pN0 (i+)(sn) 1 4.16
pN1 mi(sn) 0 0
pN1a 2 8.33
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